Navigation Links
Resverlogix Board of Directors Update
Date:9/3/2008

Provides shareholders with an update on strategic review activities

TSX Exchange Symbol: RVX

CALGARY, Sept. 3 /PRNewswire-FirstCall/ - On behalf of Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) the Board of Directors, due to the recent advancement of various discussions with third parties, feel it is prudent to update the market as to activities surrounding a previously announced strategic review process of January 25, 2007. One strategic review option currently under evaluation by the Company is an offer to out-license the Company's NexVas(TM) PR technology for cardiovascular indications to a single Asian country in order to generate non dilutive equity while continuing to further the development of our cardiovascular programs. As a result of the progression of term discussions with more than one Asian pharmaceutical group in this regard, the Board has directed management to proceed with the option for a one country licensing deal concurrently with global deal discussions. To this end, Resverlogix has received a mutually acceptable non-binding proposal for the licensing of NexVas PR and will seek to further advance negotiations. No time frame or terms will be released at this time as there is currently no guarantee that this process will result in a completed licensing deal.

The Board of Directors is also pleased to update shareholders on the ongoing strategic review process pertaining to various types of global partnership deals relating to the NexVas PR technology. Currently, there are three global pharmaceutical companies who are in the process of performing extensive due diligence on NexVas PR and other Resverlogix technologies. Management is also in ongoing discussion with numerous other groups that have shown interest in the NexVas PR technology. The Board is cautious to add that any potential transactions are subject to an extensive negotiation process and there can be no assurance that they will be finalized or that they will result in any specific transaction that will be acceptable to the Company. Management and the Board of Directors will continue to monitor ongoing developments and update the market when deemed appropriate or required.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production within one's own body. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast
2. Jan Gray Joins Resverlogix Board of Directors
3. Resverlogixs Lead Drug Featured in Key Scientific Publication
4. Industry Leaders Select Resverlogixs RVX-208
5. /C O R R E C T I O N from Source -- Resverlogix Corp./
6. Resverlogix Notice of Conference Call & Webcast
7. Resverlogix Share Option Extension
8. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
9. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
10. Resverlogix is Presenting at IAS HDL Workshop
11. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- Cousins Properties (NYSE: CUZ ) announced today ... signed a 10-year, approximately 125,000 square-foot lease at Corporate Center, ... the Westshore submarket of Tampa, FL. ... Corporate Center for their new location in Tampa ... executive officer of Cousins Properties. "Amgen is a cutting-edge global ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics Officer ... Subha Madhavan , Ph.D., will be speaking at ... Panels. On Monday, March 27, 2017, she will be ... More Usable for Research and Care" (from 10:30 a.m. ... 2017, she will be a participant in the "Making ...
(Date:3/27/2017)... ... ... PMG Research is pleased to announce its participation in the 2nd ... Boston on April 3-4, 2017. The CTC conference focuses on how the industry is ... closer to the patient. Clinical Trial Collaborations also will present an inaugural conference on ...
Breaking Biology Technology:
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
Breaking Biology News(10 mins):